Skip to main content
Top
Published in: BMC Neurology 1/2020

01-12-2020 | Electroencephalography | Case report

Immune mediated pediatric encephalitis – need for comprehensive evaluation and consensus guidelines

Authors: Julia Shekunov, Caren J. Blacker, Jennifer L. Vande Voort, Jan-Mendelt Tillema, Paul E. Croarkin, Magdalena Romanowicz

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Autoimmune encephalitis is characterized by neuropsychiatric symptoms associated with brain inflammation. The differential is usually broad and Psychiatry often collaborates with Neurology in diagnostic clarification and symptom management. At least 40% of neuroencephalitis cases are of unknown etiology which adds to difficulties in making the right diagnosis and deciding on the appropriate treatment (Granerod et al., Lancet Infect Dis 10:835-44, 2010). The aim of this case series was to present four cases with complicated psychiatric symptomatology and isolated neurologic signs and symptoms, evaluated at a large tertiary medical center and treated for suspected autoimmune encephalitis, demonstrating the complexity of diagnosis and treatment.

Case presentation

Four diagnostically challenging and heterogeneous cases displayed clinical symptomatology suggestive of autoimmune encephalitis. All cases presented with neurologic and psychiatric symptoms, but had negative autoantibody panels, normal or inconclusive magnetic resonance imaging results and non-specific cerebrospinal fluid changes. All were challenged with immunosuppressive/immunomodulatory treatments with overall poor response rates.

Conclusions

There is a heterogeneous presentation of autoimmune encephalitis in pediatric populations. In the absence of positive findings on testing, individuals who do not meet proposed criteria for seronegative encephalitis may be misdiagnosed, and/or may not respond adequately to treatment. In those cases, comprehensive evaluation and stringent application of consensus guidelines is necessary.
Appendix
Available only for authorised users
Literature
1.
go back to reference Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. The Lancet Infectious diseases. 2010;10(12):835-44. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. The Lancet Infectious diseases. 2010;10(12):835-44.
2.
go back to reference Mooneyham GC, Gallentine W, Van Mater H. Evaluation and Management of Autoimmune Encephalitis: a clinical overview for the practicing child psychiatrist. Child Adolesc Psychiatr Clin N Am. 2018;27(1):37–52.CrossRef Mooneyham GC, Gallentine W, Van Mater H. Evaluation and Management of Autoimmune Encephalitis: a clinical overview for the practicing child psychiatrist. Child Adolesc Psychiatr Clin N Am. 2018;27(1):37–52.CrossRef
3.
go back to reference Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol (Seoul, Korea). 2016;12(1):1–13.CrossRef Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol (Seoul, Korea). 2016;12(1):1–13.CrossRef
4.
go back to reference Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166–77.CrossRef Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Ann Neurol. 2018;83(1):166–77.CrossRef
5.
go back to reference Granerod J, Tam CC, Crowcroft NS, Davies NW, Borchert M, Thomas SL. Challenge of the unknown. A systematic review of acute encephalitis in non-outbreak situations. Neurology. 2010;75(10):924–32.CrossRef Granerod J, Tam CC, Crowcroft NS, Davies NW, Borchert M, Thomas SL. Challenge of the unknown. A systematic review of acute encephalitis in non-outbreak situations. Neurology. 2010;75(10):924–32.CrossRef
6.
go back to reference Van Mater H. Pediatric inflammatory brain diseases: a diagnostic approach. Curr Opin Rheumatol. 2014;26(5):553–61.CrossRef Van Mater H. Pediatric inflammatory brain diseases: a diagnostic approach. Curr Opin Rheumatol. 2014;26(5):553–61.CrossRef
7.
go back to reference Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci. 2011;23(1):90–7.CrossRef Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci. 2011;23(1):90–7.CrossRef
8.
go back to reference Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11–8.CrossRef Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11–8.CrossRef
9.
go back to reference Titulaer MJ, Leypoldt F, Dalmau J. Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Mov Disord. 2014;29(1):3–6.CrossRef Titulaer MJ, Leypoldt F, Dalmau J. Antibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis. Mov Disord. 2014;29(1):3–6.CrossRef
10.
go back to reference Hacohen Y, Wright S, Waters P, Agrawal S, Carr L, Cross H, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry. 2013;84(7):748–55.CrossRef Hacohen Y, Wright S, Waters P, Agrawal S, Carr L, Cross H, et al. Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry. 2013;84(7):748–55.CrossRef
11.
go back to reference Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.CrossRef Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.CrossRef
12.
go back to reference Stingl C, Cardinale K, Van Mater H. An update on the treatment of pediatric autoimmune encephalitis. Curr Treatm Opt Rheumatol. 2018;4(1):14–28.CrossRef Stingl C, Cardinale K, Van Mater H. An update on the treatment of pediatric autoimmune encephalitis. Curr Treatm Opt Rheumatol. 2018;4(1):14–28.CrossRef
13.
go back to reference Singh TD, Fugate JE, Rabinstein AA. The spectrum of acute encephalitis: causes, management, and predictors of outcome. Neurology. 2015;84(4):359–66.CrossRef Singh TD, Fugate JE, Rabinstein AA. The spectrum of acute encephalitis: causes, management, and predictors of outcome. Neurology. 2015;84(4):359–66.CrossRef
14.
go back to reference Randell RL, Adams AV, Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pediatr Neurol. 2018;86:66–8.CrossRef Randell RL, Adams AV, Van Mater H. Tocilizumab in refractory autoimmune encephalitis: a series of pediatric cases. Pediatr Neurol. 2018;86:66–8.CrossRef
15.
go back to reference Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129–36.CrossRef Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129–36.CrossRef
16.
go back to reference Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62(4):281–8.CrossRef Kokmen E, Naessens JM, Offord KP. A short test of mental status: description and preliminary results. Mayo Clin Proc. 1987;62(4):281–8.CrossRef
17.
go back to reference Brenton JN, Kim J, Schwartz RH. Approach to the Management of Pediatric-Onset Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis: a case series. J Child Neurol. 2016;31(9):1150–5.CrossRef Brenton JN, Kim J, Schwartz RH. Approach to the Management of Pediatric-Onset Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis: a case series. J Child Neurol. 2016;31(9):1150–5.CrossRef
18.
go back to reference Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e130.CrossRef Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e130.CrossRef
19.
go back to reference Pillai SC, Hacohen Y, Tantsis E, Prelog K, Merheb V, Kesson A, et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics. 2015;135(4):e974–84.CrossRef Pillai SC, Hacohen Y, Tantsis E, Prelog K, Merheb V, Kesson A, et al. Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome. Pediatrics. 2015;135(4):e974–84.CrossRef
20.
go back to reference Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30(3):334–44.CrossRef Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30(3):334–44.CrossRef
21.
go back to reference Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582–93.CrossRef Quek AM, Britton JW, McKeon A, So E, Lennon VA, Shin C, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582–93.CrossRef
22.
go back to reference Kirshner HS. Hashimoto’s encephalopathy: a brief review. Curr Neurol Neurosci Rep. 2014;14(9):476.CrossRef Kirshner HS. Hashimoto’s encephalopathy: a brief review. Curr Neurol Neurosci Rep. 2014;14(9):476.CrossRef
23.
go back to reference Shin YW, Lee ST, Park KI, Jung KH, Jung KY, Lee SK, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.PubMed Shin YW, Lee ST, Park KI, Jung KH, Jung KY, Lee SK, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.PubMed
24.
go back to reference Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27(11):1460–9.CrossRef Armangue T, Petit-Pedrol M, Dalmau J. Autoimmune encephalitis in children. J Child Neurol. 2012;27(11):1460–9.CrossRef
25.
go back to reference Armangue T, Titulaer MJ, Malaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162(4):850–6.e2.CrossRef Armangue T, Titulaer MJ, Malaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162(4):850–6.e2.CrossRef
26.
go back to reference Ferrafiat V, Raffin M, Deiva K, Salle-Collemiche X, Lepine A, Spodenkiewicz M, et al. Catatonia and autoimmune conditions in children and adolescents: should we consider a therapeutic challenge? J Child Adolesc Psychopharmacol. 2017;27(2):167–76.CrossRef Ferrafiat V, Raffin M, Deiva K, Salle-Collemiche X, Lepine A, Spodenkiewicz M, et al. Catatonia and autoimmune conditions in children and adolescents: should we consider a therapeutic challenge? J Child Adolesc Psychopharmacol. 2017;27(2):167–76.CrossRef
27.
go back to reference Späth PJGG, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11.CrossRef Späth PJGG, La Marra F, Kuijpers TW, Quinti I. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11.CrossRef
28.
go back to reference Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–9.CrossRef Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–9.CrossRef
29.
go back to reference Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391–419.CrossRef Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391–419.CrossRef
Metadata
Title
Immune mediated pediatric encephalitis – need for comprehensive evaluation and consensus guidelines
Authors
Julia Shekunov
Caren J. Blacker
Jennifer L. Vande Voort
Jan-Mendelt Tillema
Paul E. Croarkin
Magdalena Romanowicz
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-1605-y

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue